VSBC VITASPRING BIOMEDICAL CO. LTD.
Services-Commercial Physical & Biological Research · OTC · SEC CIK 1697884 · Fiscal year ends 01/31
Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY14.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,861.9%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets31,554.8%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.02x
Accruals ratio-2,928.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-01-31 | FY20252025-01-31 | FY20242024-01-31 | FY20232023-01-31 | FY20212022-01-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $5.61M |
| Cost of revenue | $0 | $0 | $0 | $3.33M | $3.55M |
| Gross profit | $0 | $0 | $0 | -$3.33M | $2.07M |
| SG&A expense | $385,411 | $679,914 | $1.12M | $844,836 | $941,336 |
| Operating income | -$385,411 | -$679,914 | -$1.12M | -$4.18M | $1.13M |
| Pretax income | -$385,411 | -$679,914 | -$1.12M | -$4.17M | $1.13M |
| Income tax | $29,957 | $95,008 | $0 | -$5,381 | $217,104 |
| Net income | -$415,368 | -$774,922 | -$1.12M | -$4.16M | $909,560 |
| EBITDA | -$375,454 | -$669,957 | -$1.10M | -$4.16M | $1.14M |
| EPS (diluted) | 0.00 | 0.00 | -0.01 | -0.02 | 0.00 |
| Weighted avg. shares (diluted) | 207.03M | 207.03M | 207.03M | 206.52M | 205.98M |
| Balance sheet | |||||
| Cash & equivalents | $2,084 | $272 | $13 | $29,656 | $107,212 |
| Receivables | — | $0 | $0 | $380,000 | $2.95M |
| Inventory | — | — | — | $0 | $0 |
| Current assets | $10,527 | $272 | $23,627 | $437,078 | $3.06M |
| PP&E, net | $4,149 | $14,106 | $24,063 | $49,574 | $64,636 |
| Total assets | $14,676 | $14,378 | $137,342 | $765,948 | $3.60M |
| Current liabilities | $4.45M | $4.03M | $3.49M | $3.07M | $1.74M |
| Total liabilities | $4.45M | $4.03M | $3.49M | $3.16M | $2.03M |
| Shareholders' equity | -$4.43M | -$4.02M | -$3.35M | -$2.40M | $1.58M |
| Shares outstanding | 207.03M | 207.03M | — | 152.08M | 118.59M |
| Cash flow statement | |||||
| Operating cash flow | -$2,688 | -$14,675 | -$34,920 | -$77,556 | -$269,631 |
| Capital expenditure | — | — | — | $0 | $72,997 |
| Free cash flow | — | — | — | -$77,556 | -$342,628 |
| Investing cash flow | — | — | — | $0 | -$72,997 |
| Financing cash flow | $4,500 | $14,934 | $5,277 | $0 | $50,000 |
| Depreciation & amortization | $9,957 | $9,957 | $15,062 | $15,062 | $8,361 |
| Stock-based compensation | $0 | $109,911 | $164,865 | $190,365 | $167,173 |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.